Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics clinical trials
A subsidiary of Structure Therapeutics
The registry lists 1 studies whose lead sponsor is Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 14, 2026.
- 1study on the registry
- 1open to participants now
- 1reach primary completion within a year
Coming up
1 of Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics’ studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- 1MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 1 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Open now1100%
Over the years
- 125
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics1 study
Something wrong with this grouping? Tell us on the Structure Therapeutics page.
Studies
Recruiting first, then most recently updated. Showing 1 of 1. All Structure Therapeutics studies →
- First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671RecruitingNCT07815678Phase 1/2
Sponsor listed in the registry: Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics